Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery

Launched by MEDICAL UNIVERSITY OF SOUTH CAROLINA · Jun 7, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how to improve the use of medications that help prevent dangerous blood clots in patients who have had major cancer surgery. Blood clots can be a serious problem after surgery, but many patients don’t receive the recommended medications after leaving the hospital. The researchers want to find out if educating surgeons and patients about the risks of blood clots can lead to more people getting these important medications after surgery.

To participate in this study, patients must be undergoing specific types of cancer surgeries, such as removal of the stomach or bladder, and they cannot have certain conditions, like severe kidney disease. Participants will receive information about blood clot risks when they leave the hospital and will complete a questionnaire to help researchers understand their knowledge and adherence to the prescribed medications. This study aims to improve patient care by ensuring that those at risk of blood clots receive the right support and treatment after their surgery.

Gender

ALL

Eligibility criteria

• • SURGEON CLUSTER
• Inclusion Criteria:
• • Surgeons performing cancer surgery within the Medical University of South Carolina (MUSC) system will be identified. Patients undergoing surgery for included cancers in the three hospitals will be identified using inclusion/exclusion criteria as follows. "Abdominopelvic cancer surgery" includes esophagectomy, gastrectomy, pancreatectomy, small bowel resection, colectomy, proctectomy, cystectomy, nephrectomy and hysterectomy / oophorectomy performed for a diagnosis of cancer as identified by Current Procedural Terminology (CPT) code and International Classification of Diseases, Tenth Revision (ICD-10) diagnosis code.
• Exclusion Criteria:
• • We will exclude patients receiving preoperative therapeutic anticoagulation within 30 days preoperatively, patients initiating therapeutic anticoagulation postoperatively and patients with chronic kidney disease grade 3 or higher. Patients with postoperative length of stay 30 days or greater will be excluded as ePpx duration is for 30 days postoperative.
• • PATIENT SURVEY
• Inclusion Criteria:
• • Patients undergoing surgery for included cancers in the three hospitals will be identified using inclusion/exclusion criteria as follows. "Abdominopelvic cancer surgery" includes esophagectomy, gastrectomy, pancreatectomy, small bowel resection, colectomy, proctectomy, cystectomy, nephrectomy and hysterectomy / oophorectomy performed for a diagnosis of cancer as identified by Current Procedural Terminology (CPT) code and International Classification of Diseases, Tenth Revision (ICD-10) diagnosis code.
• Exclusion Criteria:
• • We will exclude patients receiving preoperative therapeutic anticoagulation within 30 days preoperatively, patients initiating therapeutic anticoagulation postoperatively and patients with chronic kidney disease grade 3 or higher. Patients with postoperative length of stay 30 days or greater will be excluded as extended pharmacologic venous thromboembolism duration is for 30 days postoperative.
• • Lack of survey response.